Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
about
Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancerCutaneous complications of molecular targeted therapy used in oncologyUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies.Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.Epidermal growth factor receptor (EGFR) inhibitor-induced rash: a consecutive patient series that illustrates the need for rigorous palliative trialsManagement of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis.Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.E-mail and photographs: a case report of a patient-initiated diagnostic tool in the era of electronic communicationDermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases.Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer.Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
P2860
Q26774605-46CD3803-94EC-46FA-9B7B-04760DEC8E45Q28070095-B14D18D7-4CE4-429E-A3EB-0A9D0702A862Q33408049-59C63110-F84E-4C13-BF40-29D8AD61F544Q34235124-C162F855-9F95-4F46-809D-A82373BE0070Q34569143-C8A9D4DB-6501-40FC-B4B5-FFE129494920Q35584416-7207092F-CE1F-417A-A14D-E5312C9C49CBQ35913241-53CE56C9-114D-4BFB-B6E8-1D1ABDED3D2DQ36026706-FDE3064A-C4CF-491B-B7F0-4DDF1C7937A8Q37390753-3D7CBE3A-3DCE-4137-9D1F-E9BA16D1D789Q37442683-84AB76B9-4CFF-435C-A8EF-CE0E83CF77CEQ37541523-8149DB1B-948D-4C9A-981E-E180755E12B7Q37829757-644A9F0A-E9AA-494A-A331-8C222F2F7BC3Q37987802-3011AF9D-1E81-4A5E-AF13-47610EDB1FB5Q38095600-C31A8FBB-9EA8-4D89-ADED-3232FA96F1FBQ38133409-62438432-96ED-48D1-A3FA-E679F4EE0802Q38357125-6B123204-4502-4F00-BFC7-D961EAE0AE4DQ39745151-7D486563-D3A2-48B0-BD4F-B351DBD2CC56Q39898332-7B8A634B-6E63-4F3D-B75D-30D188842B85Q41018872-70F9B9E6-7321-42ED-9FF0-97F906259562Q44521642-635D9074-742E-4176-8699-AB8A10C47C0CQ53507332-C8109988-5ED0-4583-959E-70577272A3F9Q54258639-9EFDA797-3CB8-4FA2-8FCD-094233FE0C27Q54336793-95A5232E-C2A0-4FF3-A1DA-D17ECA9DE4EC
P2860
Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Clinical predictors of severe ...... r treatment group study N0147.
@ast
Clinical predictors of severe ...... r treatment group study N0147.
@en
type
label
Clinical predictors of severe ...... r treatment group study N0147.
@ast
Clinical predictors of severe ...... r treatment group study N0147.
@en
prefLabel
Clinical predictors of severe ...... r treatment group study N0147.
@ast
Clinical predictors of severe ...... r treatment group study N0147.
@en
P2093
P2860
P356
P1433
P1476
Clinical predictors of severe ...... r treatment group study N0147.
@en
P2093
Aminah Jatoi
Daniel J Sargent
Erin M Green
Kendrith M Rowland
Steven R Alberts
P2860
P304
P356
10.1159/000229751
P577
2009-07-22T00:00:00Z